News | July 26, 2022
GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr
GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022
GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022
The product will be manufactured at Lupin's facility in Nagpur, India.
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Company is investing more than €100 million in the expansion of the Halle site
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
First and only PARP inhibitor to improve invasive disease-free survival in patients
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Subscribe To Our Newsletter & Stay Updated
